sapacitabine

04/01/2012 - "Therefore, sapacitabine could be specifically effective against tumors that are deficient in this repair pathway. "
04/01/2012 - "This review summarizes results from supporting evidence for the mechanisms of action of sapacitabine, its preclinical activities and the current results of clinical trials in a variety of cancers. "
07/01/2006 - "We conducted a phase I study to define the toxicity, pharmacokinetics and antitumor activity of CS-682 in patients with advanced solid tumors. "
07/01/2006 - "A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors."
04/01/2012 - "Sapacitabine for cancer."

11/01/2018 - "The efficacy of sapacitabine in treating patients with acute myeloid leukemia."
12/01/2021 - "Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)."
01/01/2016 - "HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia."
01/01/2015 - "Sapacitabine in the treatment of acute myeloid leukemia."
01/01/2014 - "Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients."

09/01/2003 - "Thus, we have demonstrated that CS-682 is an efficacious antimetastatic agent that significantly prolongs survival in an orthotopic model of pancreatic cancer. "
03/01/2004 - "The results demonstrate that adjuvant oral administration of CS-682 for pancreatic cancer is highly effective with acceptable toxicity, suggesting its potential for cure of this disease in appropriate combinations."
03/01/2004 - "Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer."
09/01/2003 - "In this study we demonstrate the ability of a novel, p.o.-administered cytosine analogue, CS-682, to effectively prolong survival and inhibit metastatic growth in an imageable orthotopic mouse model of pancreatic cancer. "
09/01/2003 - "Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer."

05/15/2003 - "The efficacy of CS-682 was visualized in real time by MR imaging of initial seeding and subsequent growth of liver metastases. "
05/15/2003 - "These preclinical findings support the potential clinical utility of CS-682 in the treatment of liver metastasis."
09/01/2003 - "CS-682 also decreased the development of malignant ascites and the formation of metastases, which were reduced significantly in number in the diaphragm, lymph nodes, liver, and kidney. "
05/15/2003 - "The overall occurrence of metastases was decreased 62% by CS-682, 18% by DFDC, and 35% by 5-FU. "
05/15/2003 - "CS-682 was found to exhibit superior efficacy by delaying the onset and inhibiting the growth of liver metastasis compared with gemcitabine, 5-FU, and control. "

10/01/2016 - "CNDAC (2'-C-cyano-2'-deoxy-1-β-d-arabino-pentofuranosyl-cytosine, DFP10917) and its orally bioavailable prodrug, sapacitabine, are undergoing clinical trials for hematologic malignancies and solid tumors. "
04/01/2012 - "Sapacitabine is an orally bioavailable nucleoside analog prodrug that is in clinical trials for hematologic malignancies and solid tumors. "
01/01/2018 - "CNDAC, as the parent nucleoside, DFP10917, and as an oral prodrug, sapacitabine, are undergoing clinical trials for hematological malignancies and solid tumors. "
03/01/2011 - "The search terms used were clofarabine, nelarabine, forodesine, 8-chloroadenosine, LMP-420, azacitidine, decitabine, sapacitabine, troxacitabine, thiarabine and zebularine in conjunction with hematologic malignancies, leukemia and lymphoma. "